Suppr超能文献

基质金属蛋白酶作为与静脉曲张相关静脉扩张的潜在靶点。

Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

机构信息

Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA 02115, USA.

出版信息

Curr Drug Targets. 2013 Mar;14(3):287-324.

Abstract

Varicose veins (VVs) are a common venous disease of the lower extremity characterized by incompetent valves, venous reflux, and dilated and tortuous veins. If untreated, VVs could lead to venous thrombosis, thrombophlebitis and chronic venous leg ulcers. Various genetic, hormonal and environmental factors may lead to structural changes in the vein valves and make them incompetent, leading to venous reflux, increased venous pressure and vein wall dilation. Prolonged increases in venous pressure and vein wall tension are thought to increase the expression/activity of matrix metalloproteinases (MMPs). Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane- type MMPs and others. MMPs are known to degrade various components of the extracellular matrix (ECM). MMPs may also affect the endothelium and vascular smooth muscle, causing changes in the vein relaxation and contraction mechanisms. Endothelial cell injury also triggers leukocyte infiltration, activation and inflammation, which lead to further vein wall damage. The vein wall dilation and valve dysfunction, and the MMP activation and superimposed inflammation and fibrosis would lead to progressive venous dilation and VVs formation. Surgical ablation is an effective treatment for VVs, but may be associated with high recurrence rate, and other less invasive approaches that target the cause of the disease are needed. MMP inhibitors including endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, batimastat and marimastat, have been used as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. However, MMP inhibitors may have side effects especially on the musculoskeletal system. With the advent of new genetic and pharmacological tools, specific MMP inhibitors with fewer undesirable effects could be useful to retard the progression and prevent the recurrence of VVs.

摘要

静脉曲张(VVs)是一种常见的下肢静脉疾病,其特征为瓣膜功能不全、静脉反流和扩张扭曲的静脉。如果不治疗,VVs 可能导致静脉血栓形成、血栓性静脉炎和慢性静脉腿部溃疡。各种遗传、激素和环境因素可能导致静脉瓣膜结构改变,使其功能不全,导致静脉反流、静脉压升高和静脉壁扩张。静脉压和静脉壁张力的持续升高被认为会增加基质金属蛋白酶(MMPs)的表达/活性。MMPs 家族成员包括胶原酶、明胶酶、基质溶解素、基质金属蛋白酶和其他类型。MMPs 已知可降解细胞外基质(ECM)的各种成分。MMPs 还可能影响内皮细胞和血管平滑肌,导致静脉松弛和收缩机制发生变化。内皮细胞损伤还会引发白细胞浸润、激活和炎症,导致进一步的静脉壁损伤。静脉壁扩张和瓣膜功能障碍,以及 MMP 激活和叠加的炎症和纤维化,会导致静脉进行性扩张和 VVs 形成。手术消融是 VVs 的有效治疗方法,但可能与高复发率相关,需要针对疾病原因的其他微创方法。基质金属蛋白酶抑制剂,包括内源性组织抑制剂(TIMPs)和药理学抑制剂,如锌螯合剂、强力霉素、巴曲酶和马立司他,已被用作癌症、自身免疫和心血管疾病的诊断和治疗工具。然而,基质金属蛋白酶抑制剂可能有副作用,尤其是对肌肉骨骼系统。随着新的遗传和药理学工具的出现,具有较少不良作用的特异性 MMP 抑制剂可能有助于延缓进展并预防 VVs 的复发。

相似文献

2
Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
Prog Mol Biol Transl Sci. 2017;147:267-299. doi: 10.1016/bs.pmbts.2017.02.003. Epub 2017 Mar 21.
3
Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.
J Pharmacol Exp Ther. 2015 Dec;355(3):410-28. doi: 10.1124/jpet.115.227330. Epub 2015 Aug 28.
4
Matrix metalloproteinases in venous tissue remodeling and varicose vein formation.
Curr Vasc Pharmacol. 2008 Jul;6(3):158-72. doi: 10.2174/157016108784911957.
5
Mechanisms of varicose vein formation: valve dysfunction and wall dilation.
Phlebology. 2008;23(2):85-98. doi: 10.1258/phleb.2007.007027.
6
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
Biochem Pharmacol. 2008 Jan 15;75(2):346-59. doi: 10.1016/j.bcp.2007.07.004. Epub 2007 Jul 7.

引用本文的文献

1
Cosmeceutical application of extracts from the flowers, stems, and leaves of grown at different altitudes.
Front Pharmacol. 2025 May 9;16:1551134. doi: 10.3389/fphar.2025.1551134. eCollection 2025.
3
Relationship between internal diameter and vasoconstriction in human varicose veins.
J Smooth Muscle Res. 2024;60:31-38. doi: 10.1540/jsmr.60.31.
4
Key Regulators of Angiogenesis and Inflammation Are Dysregulated in Patients with Varicose Veins.
Int J Mol Sci. 2024 Jun 20;25(12):6785. doi: 10.3390/ijms25126785.
5
Factors Influencing Venous Remodeling in the Development of Varicose Veins of the Lower Limbs.
Int J Mol Sci. 2024 Jan 26;25(3):1560. doi: 10.3390/ijms25031560.
6
The multifaceted roles of matrix metalloproteinases in lung cancer.
Front Oncol. 2023 Sep 12;13:1195426. doi: 10.3389/fonc.2023.1195426. eCollection 2023.
7
9
Association between Inguinal Hernia and Arterial Disease: A Preliminary Report.
Biology (Basel). 2021 Aug 1;10(8):736. doi: 10.3390/biology10080736.

本文引用的文献

1
The history of matrix metalloproteinases: milestones, myths, and misperceptions.
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H919-30. doi: 10.1152/ajpheart.00577.2012. Epub 2012 Aug 17.
3
A genetic study of chronic venous insufficiency.
Ann Vasc Surg. 2012 Jul;26(5):636-42. doi: 10.1016/j.avsg.2011.11.036.
6
Assessment of the infiltration of inflammatory cells in the walls of thrombotic varicose veins.
Angiology. 2013 Jan;64(1):69-72. doi: 10.1177/0003319711435147. Epub 2012 Feb 1.
7
Increased activation of the hypoxia-inducible factor pathway in varicose veins.
J Vasc Surg. 2012 May;55(5):1427-39. doi: 10.1016/j.jvs.2011.10.111. Epub 2012 Jan 24.
8
Experimental hypertension triggers varicosis-like maladaptive venous remodeling through activator protein-1.
FASEB J. 2011 Oct;25(10):3613-21. doi: 10.1096/fj.11-185975. Epub 2011 Jun 17.
9
Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
J Vasc Surg. 2011 Aug;54(2):489-96. doi: 10.1016/j.jvs.2011.01.043. Epub 2011 Apr 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验